Design and rationale of the drug-coated balloon coronary angioplasty versus stenting for treatment of disease adjacent to a chronic total occlusion (Co-CTO) trial
Authors
José P.S. Henriques (ORCID: https://orcid.org/0000-0002-8969-7929)
Tuomas T. Rissanen (ORCID: https://orcid.org/0000-0002-1914-2282)
Design and rationale of the drug-coated balloon coronary angioplasty versus stenting for treatment of disease adjacent to a chronic total occlusion (Co-CTO) trial
José P.S. Henriques, Tuomas T. Rissanen, Bimmer E.P.M. Claessen, Paul Knaapen et al.
Citations
10 citations
Journal
American Heart Journal
Topics
Coronary Interventions and Diagnostics
Field-Weighted Citation Impact (FWCI)
20.06
article
Design and rationale of the drug-coated balloon coronary angioplasty versus stenting for treatment of disease adjacent to a chronic total occlusion (Co-CTO) trial
José P.S. Henriques, Tuomas T. Rissanen, Bimmer E.P.M. Claessen, Paul Knaapen, Margaret McEntegart, Yvemarie Somsen, Roel Hoek, A Nap, Ralf W. Sprengers, Jos W. R. Twisk, Ruben W. de Winter, Sebastiaan A. Kleijn, Jiawei Wu, James Spratt, Niels Verouden, Akiko Maehara
article en
10 citations
Abstract
No abstract available for this paper.
Publication Tag
American Heart JournalVol. 288
Institutions
NewYork–Presbyterian Hospital (US), Columbia University Irving Medical Center (US), St James's University Hospital (GB), North Karelia Central Hospital (FI), Amsterdam Neuroscience (NL), St George's Hospital (GB), Amsterdam University Medical Centers (NL), Vrije Universiteit Amsterdam (NL), University of Amsterdam (NL)
Funders
Amgen, Sanofi, Boston Scientific Corporation, InfraRedx, Nipro, Abiomed, Novo Nordisk, Abbott Vascular